Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

被引：39
作者：
van der Kooij, M. K. [1 ]
Joosse, A. [1 ]
Speetjens, F. M. [1 ]
Hospers, G. A. P. [2 ]
Bisschop, C. [2 ]
de Groot, J. W. B. [3 ]
Koornstra, R. [4 ]
Blank, C. U. [5 ]
Kapiteijn, E. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Clin Oncol, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands
[3] Isala, Dept Med Oncol, Zwolle, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[5] Netherlands Canc Inst NKI AVL, Dept Med Oncol, Amsterdam, Netherlands
来源：
ACTA ONCOLOGICA | 2017年 / 56卷 / 01期
关键词：
IPILIMUMAB; TRIAL;
D O I：
10.1080/0284186X.2016.1260773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：101 / 103
页数：3
相关论文
共 50 条
  • [21] Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
    Algazi, Alain P.
    Tsai, Katy K.
    Shoushtari, Alexander N.
    Munhoz, Rodrigo R.
    Eroglu, Zeynep
    Piulats, Josep M.
    Ott, Patrick A.
    Johnson, Douglas B.
    Hwang, Jimmy
    Daud, Adil I.
    Sosman, Jeffrey A.
    Carvajal, Richard D.
    Chmielowski, Bartosz
    Postow, Michael A.
    Weber, Jeffrey S.
    Sullivan, Ryan J.
    CANCER, 2016, 122 (21) : 3344 - 3353
  • [22] The use of pembrolizumab for the treatment of metastatic uveal melanoma
    Kottschade, Lisa A.
    McWilliams, Robert R.
    Markovic, Svetomir N.
    Block, Matthew S.
    Bisneto, Jose Villasboas
    Pham, Anthony Q.
    Esplin, Brandt L.
    Dronca, Roxana S.
    MELANOMA RESEARCH, 2016, 26 (03) : 300 - 303
  • [23] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
    Pollack, M. H.
    Betof, A.
    Dearden, H.
    Rapazzo, K.
    Valentine, I.
    Brohl, A. S.
    Ancell, K. K.
    Long, G. V.
    Menzies, A. M.
    Eroglu, Z.
    Johnson, D. B.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 250 - 255
  • [24] Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab
    Goutam, Siddhartha
    Stukalin, Igor
    Ewanchuk, Benjamin
    Sander, Michael
    Ding, Philip Q.
    Meyers, Daniel E.
    Heng, Daniel
    Cheung, Winson Y.
    Cheng, Tina
    CURRENT ONCOLOGY, 2022, 29 (10) : 7695 - 7704
  • [25] Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup
    Rubatto, Marco
    Fava, Paolo
    Stanganelli, Ignazio
    Ribero, Simone
    Pigozzo, Jacopo
    Di Giacomo, Anna Maria
    Ridolfi, Laura
    Tronconi, Maria Chiara
    Trojaniello, Claudia
    Bersanelli, Melissa
    Garutti, Mattia
    Indini, Alice
    De Risi, Ivana
    De Tursi, Michele
    Merelli, Barbara
    Morgese, Francesca
    Occelli, Marcella
    Cappellini, Gian Carlo Antonini
    Poletto, Stefano
    Fedele, Dahlia
    Brugnara, Sonia
    Frisinghelli, Michela
    Formisano, Luigi
    Conca, Raffaele
    Tucci, Marco
    Russillo, Michelangelo
    Ceroni, Luca
    Queirolo, Paola
    Targato, Giada
    Strippoli, Sabino
    Mandala, Mario
    Guida, Michele
    Quaglino, Pietro
    EUROPEAN JOURNAL OF CANCER, 2023, 187 : 25 - 35
  • [26] Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
    Indini, Alice
    Di Guardo, Lorenza
    Cimminiello, Carolina
    Prisciandaro, Michele
    Randon, Giovanni
    De Braud, Filippo
    Del Vecchio, Michele
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (02) : 511 - 521
  • [27] Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy
    Hossain, Sultana Mehbuba
    Gimenez, Gregory
    Stockwell, Peter
    Weeks, Robert
    Almomani, Suzan
    Jones, Gregory T.
    Ratajska, Magdalena
    Shuen, Mathew
    Bhat, Basharat
    Rys, Janusz
    Cybulska-Stopa, Bozena
    Harazin-Lechowska, Agnieszka
    Rodger, Euan
    Jackson, Christopher
    Chatterjee, Aniruddha
    Eccles, Michael R.
    CANCER LETTERS, 2025, 618
  • [28] Home anti-PD1 immunotherapy for melanoma: results of a patient and nursing satisfaction survey
    Truong, Thu Thao
    Lapassat, Marie
    Belbezier, Aude
    Leccia, Marie-Therese
    Mouret, Stephane
    Lemoigne, Aude
    Charles, Julie
    Trabelsi, Sabiha
    EUROPEAN JOURNAL OF DERMATOLOGY, 2025, 35 (01) : 31 - 37
  • [29] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
    Afzal, Muhammad Zubair
    Mabaera, Rodwell
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [30] Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors
    Gomes, Jessica Ribeiro
    Schmerling, Rafael A.
    Haddad, Carolina K.
    Racy, Douglas J.
    Ferrigno, Robson
    Gil, Erlon
    Zanuncio, Pedro
    Buzaid, Antonio C.
    JOURNAL OF IMMUNOTHERAPY, 2016, 39 (09) : 367 - 372
12345